ABBV
Price
$206.69
Change
+$2.01 (+0.98%)
Updated
Aug 15 closing price
Capitalization
365.13B
68 days until earnings call
RHHBY
Price
$39.58
Change
+$0.92 (+2.38%)
Updated
Aug 15 closing price
Capitalization
254.82B
67 days until earnings call
Interact to see
Advertisement

ABBV vs RHHBY

Header iconABBV vs RHHBY Comparison
Open Charts ABBV vs RHHBYBanner chart's image
ABBVIE
Price$206.69
Change+$2.01 (+0.98%)
Volume$4.43M
Capitalization365.13B
Roche Holding
Price$39.58
Change+$0.92 (+2.38%)
Volume$2.44M
Capitalization254.82B
ABBV vs RHHBY Comparison Chart in %
Loading...
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RHHBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABBV vs. RHHBY commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Hold and RHHBY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (ABBV: $206.69 vs. RHHBY: $39.58)
Brand notoriety: ABBV: Notable vs. RHHBY: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: ABBV: 79% vs. RHHBY: 180%
Market capitalization -- ABBV: $365.13B vs. RHHBY: $254.82B
ABBV [@Pharmaceuticals: Major] is valued at $365.13B. RHHBY’s [@Pharmaceuticals: Major] market capitalization is $254.82B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $628.62B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $87.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABBV’s FA Score shows that 4 FA rating(s) are green whileRHHBY’s FA Score has 1 green FA rating(s).

  • ABBV’s FA Score: 4 green, 1 red.
  • RHHBY’s FA Score: 1 green, 4 red.
According to our system of comparison, ABBV is a better buy in the long-term than RHHBY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABBV’s TA Score shows that 6 TA indicator(s) are bullish while RHHBY’s TA Score has 6 bullish TA indicator(s).

  • ABBV’s TA Score: 6 bullish, 4 bearish.
  • RHHBY’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, ABBV is a better buy in the short-term than RHHBY.

Price Growth

ABBV (@Pharmaceuticals: Major) experienced а +4.36% price change this week, while RHHBY (@Pharmaceuticals: Major) price change was +3.53% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.35%. For the same industry, the average monthly price growth was +5.72%, and the average quarterly price growth was +12.95%.

Reported Earning Dates

ABBV is expected to report earnings on Oct 24, 2025.

RHHBY is expected to report earnings on Oct 23, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+2.35% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABBV($365B) has a higher market cap than RHHBY($255B). ABBV has higher P/E ratio than RHHBY: ABBV (98.42) vs RHHBY (21.71). ABBV YTD gains are higher at: 19.519 vs. RHHBY (17.248). RHHBY has less debt than ABBV: RHHBY (33B) vs ABBV (69.9B).
ABBVRHHBYABBV / RHHBY
Capitalization365B255B143%
EBITDAN/A18B-
Gain YTD19.51917.248113%
P/E Ratio98.4221.71453%
RevenueN/A63.5B-
Total CashN/A12B-
Total Debt69.9B33B212%
FUNDAMENTALS RATINGS
ABBV vs RHHBY: Fundamental Ratings
ABBV
RHHBY
OUTLOOK RATING
1..100
1963
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
10
Undervalued
PROFIT vs RISK RATING
1..100
1098
SMR RATING
1..100
1498
PRICE GROWTH RATING
1..100
2560
P/E GROWTH RATING
1..100
1552
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RHHBY's Valuation (10) in the null industry is significantly better than the same rating for ABBV (89) in the Pharmaceuticals Major industry. This means that RHHBY’s stock grew significantly faster than ABBV’s over the last 12 months.

ABBV's Profit vs Risk Rating (10) in the Pharmaceuticals Major industry is significantly better than the same rating for RHHBY (98) in the null industry. This means that ABBV’s stock grew significantly faster than RHHBY’s over the last 12 months.

ABBV's SMR Rating (14) in the Pharmaceuticals Major industry is significantly better than the same rating for RHHBY (98) in the null industry. This means that ABBV’s stock grew significantly faster than RHHBY’s over the last 12 months.

ABBV's Price Growth Rating (25) in the Pharmaceuticals Major industry is somewhat better than the same rating for RHHBY (60) in the null industry. This means that ABBV’s stock grew somewhat faster than RHHBY’s over the last 12 months.

ABBV's P/E Growth Rating (15) in the Pharmaceuticals Major industry is somewhat better than the same rating for RHHBY (52) in the null industry. This means that ABBV’s stock grew somewhat faster than RHHBY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABBVRHHBY
RSI
ODDS (%)
Bearish Trend 3 days ago
31%
Bullish Trend 4 days ago
57%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
43%
Bullish Trend 4 days ago
60%
Momentum
ODDS (%)
Bullish Trend 3 days ago
72%
Bearish Trend 4 days ago
57%
MACD
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 4 days ago
59%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
58%
Bullish Trend 4 days ago
49%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
60%
Bearish Trend 4 days ago
54%
Advances
ODDS (%)
Bullish Trend 3 days ago
57%
Bullish Trend 4 days ago
51%
Declines
ODDS (%)
Bearish Trend 18 days ago
45%
Bearish Trend 7 days ago
46%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
40%
Bullish Trend 4 days ago
59%
Aroon
ODDS (%)
Bullish Trend 3 days ago
56%
Bullish Trend 4 days ago
38%
View a ticker or compare two or three
Interact to see
Advertisement
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RHHBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VRDN18.540.10
+0.54%
Viridian Therapeutics
BEAGU10.70N/A
N/A
Bold Eagle Acquisition Corp
FTAIN25.29-0.02
-0.08%
FTAI Aviation Ltd
CRT8.69-0.06
-0.69%
Cross Timbers Royalty Trust
HUSA9.61-0.36
-3.61%
Houston American Energy Corp

ABBV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with PFE. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABBV
1D Price
Change %
ABBV100%
+0.98%
PFE - ABBV
55%
Loosely correlated
+0.12%
AMGN - ABBV
52%
Loosely correlated
+2.13%
BIIB - ABBV
42%
Loosely correlated
+2.71%
JNJ - ABBV
42%
Loosely correlated
+1.10%
NVS - ABBV
40%
Loosely correlated
+1.74%
More

RHHBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, RHHBY has been loosely correlated with RHHVF. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if RHHBY jumps, then RHHVF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RHHBY
1D Price
Change %
RHHBY100%
+2.38%
RHHVF - RHHBY
66%
Loosely correlated
+4.32%
RHHBF - RHHBY
36%
Loosely correlated
+0.99%
ABBV - RHHBY
21%
Poorly correlated
+0.98%
JNJ - RHHBY
20%
Poorly correlated
+1.10%
CHGCY - RHHBY
20%
Poorly correlated
+2.36%
More